土耳其慢性乙型肝炎患者中甲型肝炎病毒抗体的血清流行率

Seroprevalence of Hepatitis A Virus Antibodies among the Patients with Chronic Hepatitis B in Turkey.

作者信息

Tulek Necla, Ozsoy Metin, Moroglu Cigdem, Cagla Sonmezer Meliha, Temocin Fatih, Tuncer Ertem Gunay, Sebnem Erdinc Fatma

机构信息

Department of Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Turkey.

出版信息

Euroasian J Hepatogastroenterol. 2015 Jul-Dec;5(2):95-97. doi: 10.5005/jp-journals-10018-1143. Epub 2016 Jul 9.

DOI:10.5005/jp-journals-10018-1143

PMID:29201701

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5578535/

Abstract

BACKGROUND

Hepatitis A virus (HAV) can cause significant pathology in patients with chronic hepatitis B virus (HBV), however, HAV can be prevented by vaccination. The aim of this study was to determine the implication of vaccination against HAV vaccine in patients with chronic hepatitis B.

MATERIALS AND METHODS

The seroprevalence of anti-HAV IgG antibodies was investigated in the patients with chronic hepatitis B. Anti-HAV IgG antibodies were detected by commercially available ELISA kit.

RESULTS

A total of 673 patients (354 males, 319 females with age range of 17-78 years) with chronic hepatitis B were included the study. Hepatitis A virus seropositivity rate was 34% in the patients younger than 20 years, 79% in the age group of 20 to 29 years, and 100% after 35 years of age.

DISCUSSION

Hepatitis A virus vaccination may be recommended for young adult patients with chronic hepatitis B in Turkey.

HOW TO CITE THIS ARTICLE

Tulek N, Ozsoy M, Moroglu C, Sonmezer MC, Temocin F, Ertem GT, Erdinc FS. Seroprevalence of Hepatitis A Virus Antibodies among the Patients with Chronic Hepatitis B in Turkey. Euroasian J Hepato-Gastroenterol 2015;5(2):95-97.

摘要